Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products FDA appropriations and staffing, specifically at CBER and OTP FDA oversight, including adaptive regulatory pathways for cell and gene therapies Value-based payment legislation and related CMS regulations Biologics regulation Prescription Drug User Fee Act (PDUFA) Medicaid Medicare NIH appropriations HHS oversight HHS staffing and OPM issues Federal support of medical research Pharmaceutical tariffs Biotechnology manufacturing
2026 · 3rd Quarter (July 1 - Sep 30)
ALLIANCE FOR REGENERATIVE MEDICINE
Filed by ALLIANCE FOR REGENERATIVE MEDICINE.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 19, 2026
- Income
- Not reported
- Expenses
- $120,000.00
- Registrant
- ALLIANCE FOR REGENERATIVE MEDICINE
- Filing UUID
- 20b76a7f-bfdb-4ec3-8319-dfcd9945ba0a
- Termination date
- Not reported
Expense method: C
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.